Trial Profile
Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Ixabepilone (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 29 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 26 Jun 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 05 Jun 2012 Planned end date changed from 1 Nov 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.